Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer
A Podolski-Renić, AČ Gašparović, A Valente… - European Journal of …, 2024 - Elsevier
Overcoming multidrug resistance (MDR) is one of the major challenges in cancer therapy. In
this respect, Schiff base-related compounds (bearing a R 1 R 2 Cdouble bondNR 3 bond) …
this respect, Schiff base-related compounds (bearing a R 1 R 2 Cdouble bondNR 3 bond) …
Novel Platinum (IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis
Z Liu, J Cai, G Jiang, M Wang, C Wu, K Su, W Hu… - European Journal of …, 2024 - Elsevier
Platinum-based chemotherapeutics are widely used for cancer treatment but are frequently
limited because of dosage-dependent side effects and drug resistance. To attenuate these …
limited because of dosage-dependent side effects and drug resistance. To attenuate these …
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C
Aims To investigate the collateral sensitivity (CS) of ABCB1-positive multidrug resistant
(MDR) colorectal cancer cells to the survivin inhibitor MX106–4C and the mechanism …
(MDR) colorectal cancer cells to the survivin inhibitor MX106–4C and the mechanism …
Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug …
GZ Yang, L Wang, K Gao, X Zhu, LG Lou… - Journal of Medicinal …, 2024 - ACS Publications
Inspired by the structure of dysoxylactam A (DLA) that has been demonstrated to reverse P-
glycoprotein (P-gp)-mediated multidrug resistance (MDR) effectively, 61 structurally …
glycoprotein (P-gp)-mediated multidrug resistance (MDR) effectively, 61 structurally …
[HTML][HTML] Drug resistance mechanisms in cancers: Execution of pro-survival strategies
PK Dhanyamraju - Journal of Biomedical Research, 2024 - ncbi.nlm.nih.gov
One of the quintessential challenges in cancer treatment is drug resistance. Several
mechanisms of drug resistance have been described to date, and new modes of drug …
mechanisms of drug resistance have been described to date, and new modes of drug …
Copper (II) Complexes with Isomeric Morpholine-Substituted 2-Formylpyridine Thiosemicarbazone Hybrids as Potential Anticancer Drugs Inhibiting Both …
MNM Milunovic, K Ohui, I Besleaga… - Journal of Medicinal …, 2024 - ACS Publications
The development of copper (II) thiosemicarbazone complexes as potential anticancer
agents, possessing dual functionality as inhibitors of R2 ribonucleotide reductase (RNR) …
agents, possessing dual functionality as inhibitors of R2 ribonucleotide reductase (RNR) …
Frequency-dependent ecological interactions increase the prevalence, and shape the distribution, of preexisting drug resistance
The evolution of resistance remains one of the primary challenges for modern medicine,
from infectious diseases to cancers. Many of these resistance-conferring mutations often …
from infectious diseases to cancers. Many of these resistance-conferring mutations often …
[HTML][HTML] Theoretical understanding of evolutionary dosing following tumor dynamics
Recent preclinical and clinical studies have suggested that evolution-based cancer
therapies exploiting intratumor competition can significantly delay resistance. Various …
therapies exploiting intratumor competition can significantly delay resistance. Various …
Complex formation of ML324, the histone demethylase inhibitor, with essential metal ions: Relationship between solution chemistry and anticancer activity
H Kovács, T Jakusch, NV May, S Tóth… - Journal of Inorganic …, 2024 - Elsevier
Abstract N-(3-(dimethylamino) propyl-4-(8-hydroxyquinolin-6-yl) benzamide (ML324, HL) is
a potent inhibitor of the iron-containing histone demethylase KDM4, a recognized potential …
a potent inhibitor of the iron-containing histone demethylase KDM4, a recognized potential …